Benlysta 400 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26F9KK3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,560
Award facts
- Contract value 100% obligated
- $14,560.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,560.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a biologic medication used to treat systemic lupus erythematosus and other autoimmune conditions. The contract, with an ultimate completion date of February 2, 2026, represents a non-set-aside competitive award to support federal healthcare procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with parent company Cencora, Inc. providing organizational oversight. This delivery order is issued under Cencora's larger Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 31, 2031, which provides a comprehensive global pharmaceutical support vehicle for military healthcare programs.
As a leading pharmaceutical distributor, AmerisourceBergen supplies critical medications and medical commodities across multiple therapeutic domains to military treatment facilities and federal health systems worldwide. The company's substantial IDC with DLA demonstrates its capability to fulfill specialty pharmaceutical requirements through firm fixed-price arrangements. This particular delivery order for Benlysta reflects the company's role in supporting Department of Defense medical supply chains with essential biologic medications required for treating service members and beneficiaries with autoimmune conditions. The competitively awarded status and established vendor relationship underscore AmerisourceBergen's position as a trusted federal pharmaceutical supplier within the defense healthcare ecosystem.
Quick answers
Who was awarded contract SPE2DR26F9KK3?
SPE2DR26F9KK3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26F9KK3 worth?
The government has obligated $14,560 on SPE2DR26F9KK3.
Is contract SPE2DR26F9KK3 an order under another contract?
Yes. SPE2DR26F9KK3 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9KK3 competed?
The extent of competition for SPE2DR26F9KK3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award